License Category

Setting

Interferon alpha 2b (1)

Reg. name: Intron A®

Class: Interferon

Intron A® is indicated for the initial treatment of clinically aggressive Follicular Lymphoma (FL) in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older

KTE-C19 (1)

Reg. name: Yescarta™ (axicabtagene ciloleucel)

Class: Chimeric antigen receptor T-cell

Yescarta™ is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma

Professional society

The European Lymphoma Institute is comprised of a network of top European specialists in the field of lymphoma who are dedicated to research, training and education. Together they look to define strategies to analyse and characterize lymphoma and its common diagnostic procedures and therapeutic standards, as well as to facilitate clinical and fundamental research. This all results in the advancement of lymphoma research and it guarantees equal access for all patients to the best possible care.